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Compared with acute pain that arises suddenly in response to a specific injury and
is usually treatable, chronic pain persists over time, and is often resistant to medical
treatment. Because of the heterogeneity of chronic pain origins, satisfactory therapies
for its treatment are lacking, leading to an urgent need for the development of new
treatments. The leading approach in drug design is selective compounds, though they
are often less effective and require chronic dosing with many side effects. Herein, we
review novel approaches to drug design for the treatment of chronic pain represented
by dual-acting compounds, which operate at more than one biological target. A number
of studies suggest the involvement of the cannabinoid and vanilloid receptors in pain.
Interestingly cannabinoid system is in interrelation with other systems that comprise
lipid mediators: prostaglandins, produced by COX enzyme. Therefore, in the present
review, we summarize the role of dual-acting molecules (FAAH/TRPV1 and FAAH/COX-2
inhibitors) that interact with endocannabinoid and endovanillinoid systems and act as
analgesics by elevating the endogenously produced endocannabinoids and dampening
the production of pro-inflammatory prostaglandins. The plasticity of the endocannabinoid
system (ECS) and the ability of a single chemical entity to exert an activity on two receptor
systems has been developed and extensively investigated. Here, we review up-to-date
pharmacological studies on compounds interacting with FAAH enzyme together with
TRPV1 receptor or COX-2 enzyme respectively. Multi-target pharmacological intervention
for treating pain may lead to the development of original and efficient treatments.
Keywords: FAAH, TRPV1, COXs, endocannabinoid system, dual acting compounds, pain
Abbreviations: 2-AG, 2-arachidonoyl-glycerol; AA-5-HT, N-arachidonoyl-serotonin; AEA, N-arachidonylethanolamide,
anandamide; AMG517, N-[4-[[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]-acetamide; ARN2508,
10r (±)-2-[3-fluoro-4-[3-(hexylcarbamoyloxy)phenyl]phenyl]propanoic acid; CB1, cannabinoid receptor 1; CB2,
cannabinoid receptor 2; CNS, central nervous system; COX, cyclooxygenase; ECS, endocannabinoid system; FAAH,
fatty acid amide hydrolase; I-RTX, iodoresiniferatoxin; LOX, lipoxygenase; NAGly, N-arachidonoyl glycine; NSAID,
non-steroidal anti-inflammatory drug; OEA, oleoylethanolamide; OMDM-198, 3-[((chloro)pyridin-2-yl)-3-phenyl]-
carbamate; PAG, periaqueductal gray; PEA, palmitoylethanolamide; PF-3845, 4-(3-(5-(trifluoromethyl)pyridin-2-
yloxy)benzyl)-N-(pyridin-3-yl)piperidine-1-carboxamide; PF04457845, N-pyridazin-3-yl-4-[(3-[5-(trifluoromethyl)pyridin-
2-yl]oxyphenyl)methylidene]piperidine-1-carboxamide; PG, prostaglandins; PGI, prostacyclins; SB-366,791, (E)-3-(4-
Chlorophenyl)-N-(3-methoxyphenyl)prop-2-enamide; TRPV1, transient receptor potential cation channel subfamily V
member 1; TXA, thromboxanes; URB597, cyclohexylcarbamic acid 3-carbamoyl-biphenyl-3-yl ester.
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INTRODUCTION
Pain is defined by the International Association for the Study
of Pain as an unpleasant sensory and/or emotional experience
associated with actual or potential tissue damage (Bonica, 1979).
Acute pain is important for the diagnosis and localization of the
disease process and to avoid or minimize tissue damage. In a
situation where the pain sensation remains despite mitigating the
immediate cause, it loses its warning and defensive characteristics
and becomes a disease itself, which is challenging to treat because
of the heterogeneity of its origin. None of the currently available
therapies provide sufficient relief for patients; at the same time,
they all have risks of complications and a number of adverse
effects as incidence increases with age (Ray et al., 2007; Gallagher
and Rosenthal, 2008; Williams et al., 2013). Due to the aging
population in developed countries and the lack of satisfactory
therapies, chronic pain is a worldwide disease that requires the
development of new treatments. One possible approach focuses
on the modulation of endogenously produced compounds.
The lipophilic molecule anandamide (AEA), that is an integral
part of the endocannabinoid system (ECS), also binds to the
transient receptor potential cation channel subfamily V member
1 (TRPV1); consequently, AEA is now frequently referred to as
an “endovanilloid.” A promising approach to retain the analgesic
effects of cannabinoid activation, while avoiding the undesirable
results of its global action is to elevate endogenously produced
endocannabinoids by inhibiting their hydrolytic degradation.
Fatty acid amide hydrolase (FAAH) hydrolyzes AEA and other
lipid signaling molecules, which makes it a good target for
this new therapeutic method. Moreover, ECS is interrelated
with other systems that comprise lipid mediators such as
prostaglandins/leukotrienes, contributing to the chronic pain
development (Huwiler and Pfeilschifter, 2009). Additionally,
compounds with primary actions upon cyclooxygenase (COX),
involved in pain processing, also interact with ECS, including
having the ability to directly inhibit FAAH (Fowler, 2007;
Guindon and Hohmann, 2008).
Recent studies suggest that inhibiting FAAH will not have
as significant efficacy as expected in chronic pain patient
groups (Huggins et al., 2012). Therefore, it could be more
relevant for future research to take into account a new
paradigm—a multi-therapeutic strategy combining the action
on FAAH, TRPV1, and COX-2. Here, we review up-to-
date studies on dual-acting compounds that interact with the
endocannabionid/endovanilloid and COX systems, which may
be beneficial for the treatment of chronic pain (the basis
of molecular interactions between the systems is shown in
Figure 1).
SINGLE TARGET: SUCCESS OR DEFEAT?
CB1 and CB2 Agonism
In the recent years, considerable progress has been made in
understanding the role of the ECS in the modulation of pain
processing. The system includes cannabinoid receptors 1 (CB1)
and 2 (CB2), endogenous agonists called endocannabinoids: AEA
and 2-arachidonyl glycerol (2-AG) and enzymes involved in their
biosynthesis and degradation. Endocannabinoids are produced
in injured tissues to suppress sensitization and inflammation
by activation of CB1 and CB2 (Piomelli and Sasso, 2014).
The key enzyme responsible for the catabolism of AEA is
FAAH. However, AEA can also be metabolized by COX-2
and lipoxygenase 12/15 (LOX12/15). COX-2 metabolizes AEA
to prostaglandins (PG), which are involved in inflammatory
response (Kozak et al., 2002; Yang et al., 2005; Fowler, 2007).
CB1 receptors expressed in the peripheral and central nervous
system (CNS) are responsible for the conducting of pain signaling
(Richardson et al., 1998). CB2 receptors expressed in immune
cells (also microglia), regulate the neuro-immune interactions
and interfere with the inflammatory hyperalgesia, thus also
playing an important role in nociception (Malek et al., 2015b;
Mecha et al., 2015). Endocannabinoids have been shown to
behave as analgesics in models of both acute nociception and
chronic pain such as inflammation (Pernía-Andrade et al.,
2009) and painful neuropathy (Toth et al., 2010; La Porta
et al., 2013). The main limitation of exogenous cannabinoid
receptor agonists is the number of CNS side effects, including
dysphoria, movement disorders, dizziness, memory loss, drug
abuse potential, and dependence (Thaler et al., 2011). An
alternative approach that may prevent the occurrence of these
side effects is the stimulation of endogenous mechanisms that
regulate ECS activity (Lichtman and Chapman, 2011; Lomazzo
et al., 2015).
FAAH Inhibition
Endogenous cannabinoids are synthesized “on demand” in areas
of cellular stress and therefore do not produce CB1 agonist
side effects (Di Marzo and Petrosino, 2007). Unfortunately,
locally released endocannabinoids have a very short half-life
due to efficient enzymatic degradation (Deutsch and Chin,
1993; Ahn et al., 2008). Therefore, a subsequent grip point
for pain therapies is FAAH, which is responsible for the
degradation of AEA and other related fatty acid amides including
N-palmitoylethanolamine (PEA), oleoylethanolamine (OEA),
N-arachidonoyl glycine (NAGly; Bisogno et al., 2002; Khanna
and Alexander, 2011). A series of in vivo experiments proved
that genetic or pharmacological inactivation of FAAH results
in elevation of endocannabinoids in the spinal cord and brain
stem (Lichtman et al., 2004; De Lago et al., 2005). FAAH
inhibition, rather than its deletion, may offer a distinctive
strategy for the treatment of chronic pain, because no genotypic
differences in pain behavior were evident in chronic pain models
(Lichtman et al., 2004; Kinsey et al., 2009). FAAH inhibition
was shown to cause anti-nociceptive, anti-inflammatory or anti-
edemic effects in numerous acute (Holt et al., 2005), chronic
(Jayamanne et al., 2006), and neuropathic pain animal models
(Jhaveri et al., 2006; Kinsey et al., 2009; Guindon et al.,
2013). Nevertheless, FAAH inhibitors (like URB957) are not
optimal due to some limitations. Tissue-specific changes in
the sensitivity to URB597 in neuropathic pain in rats, which
may arise as a result of changes in FAAH activity, metabolic
pathways, and tissue pH were reported (Chang et al., 2006;
Paylor et al., 2006). Due to the differential effects of URB597
in carrageenan-induced inflammation and spinal nerve ligation
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FIGURE 1 | Schematic representation of a mechanism of action for cannabinoid based multi-target drugs. The novel strategy for the pain treatment is
based on altering more than one enzymatic reaction and/or nociceptive pathway. Anandamide (AEA) is hydrolyzed into arachidonic acid (AA) and ethanolamine (ETA)
principally by fatty acid amide hydrolase (FAAH). In addition to its hydrolysis by FAAH, AEA is metabolized by COX-2. On the other hand, COX metabolizes AA, leading
to increase in pro-inflammatory prostaglandins (PG). AEA can act on transient receptor potential cation channel subfamily V member 1 (TRPV1) activating
pro-nociceptive pathways or through cannabinoid receptor 1/2 (CB1/2) pathway leading to alleviation of pain. Although, in the molecular stress conditions elevation of
AEA occurs, FAAH and COX quickly metabolize it. Therefore, there are three pathways that may increase anti-nociceptive properties of AEA; (1) inhibition of FAAH
enzyme, that leads to an increase in AEA level and a decrease in AA level; (2) inhibition of COX enzyme, that leads to an increase in AEA level and a decrease in PG
level; (3) antagonism of TRPV1 receptor, which prevents activation of pro-nociceptive pathway by AEA. Action on more than one molecular target lowers the
redundancy of the system and may lead to obtaining more stable and robust response in pain alleviation. (PGI—prostacyclins; TXA—thromboxanes).
models, efforts aimed at optimizing the clinical efficacy of
FAAH inhibitors should be revised and redesigned (Di Marzo,
2012; Okine et al., 2012). Similarly, despite many promising
preclinical results in various chronic pain models (Ahn et al.,
2011), one of the most potent FAAH inhibitors, PF-04457845,
has failed to show efficacy in humans in a randomized,
placebo-controlled phase II clinical trial (Di Marzo, 2012;
Huggins et al., 2012). Moreover, safety of FAAH inhibitors
became questioned after “first-in-human” trial to test safety
of BIA 10-2474 in healthy volunteers, which concluded with
one person dead and five more hospitalized. The probable
cause of the failure is unjustified dose, 80 times higher than
that presumed to induce total FAAH inhibition, used in the
study1.
1“Version anglaise: Minutes of the Temporary Specialist Scientific Committee
(TSSC) meeting on “FAAH (Fatty Acid Amide Hydrolase) Inhibitors” of
15/02/2016 (08/03/2016).” Agence Nationale de Sécurité du Médicament et des
Produits de Santé (ANSM).
TRPV1 Antagonism
TRPV1 has emerged as a promising target for the development
of new analgesic and anti-inflammatory drugs. TRPV1 is a
non-selective ion channel that is highly associated with pain
nociception and linked to ECS through the common agonist AEA
(Zygmunt et al., 1999; Van der Stelt et al., 2005; Lizanecz et al.,
2006). This polymodal pain transducer is known to be expressed
in peripheral sensory afferents (Singh Tahim et al., 2005; Ikeda-
Miyagawa et al., 2015), spinal cord (Kanai et al., 2006; Horvath
et al., 2008), and some brain stem nuclei involved in nociception,
including periaqueductal gray matter (PAG) and cingulate cortex
(Roberts et al., 2004; Cristino et al., 2006; Starowicz et al., 2007).
A growing body of evidence suggests that TRPV1 is essential
in driving nociceptive response (Davis et al., 2000; Immke
and Gavva, 2006; Horvath et al., 2008). TRPV1-knockout mice
exhibited attenuated inflammation-induced hyperalgesia, while
receptor blockade and desensitization caused analgesia (Karai
et al., 2004; Bölcskei et al., 2005). Furthermore, enhanced
TRPV1 expression and increased TRPV1 sensitivity to AEA
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during inflammation and neuropathic conditions has been
described previously (De Petrocellis et al., 2001; Baamonde
et al., 2005; Singh Tahim et al., 2005). Unfortunately, off-target
effects of TRPV1 modulation on thermoregulation are widely
described. TRPV1 activation results in hypothermia, whereas
antagonizing TRPV1 causes hyperthermia, which accounted for
the failure of AMG517 during a phase I clinical trial (Di Marzo
et al., 2000; Swanson et al., 2005; Gavva et al., 2008). Nevertheless,
TRPV1 antagonism has still emerged as an interesting strategy
to alleviate pain, especially with simultaneous action on either
FAAH and/or COX-2, which could allow lower doses to be used
(Lee et al., 2015; Malek et al., 2015a, 2016).
COX-2 Antagonism
The basis for the use of non-steroidal anti-inflammatory drugs
(NSAIDs) for the treatment of pain and inflammation is
COX inhibition. Cyclooxygenases are enzymes that catalyze the
conversion of membrane phospholipids to prostanoids, which
include PG, prostacyclins (PGI) essential for intestine and kidney
functioning, and thromboxanes (TXA), responsible for platelet
aggregation. The two COX isozymes are COX-1 and COX-
2. COX-1 is characterized by constitutive expression in tissues
and COX-2 is an induced isoform with low baseline expression
in human tissues that can be induced during a response to
extracellular and intracellular stimuli. The increase in COX-
2 expression elevates proinflammatory cytokine, mitogen and
growth factor levels (Smith et al., 1996), as well it plays a
key role in the transmission of pain to the brain and spinal
cord (Ito et al., 2001). Moreover, blocking COXs can influence
the ECS by stopping the conversion of endocannabinoids into
prostanoid-like derivatives, which may be of benefit for the
treatment of chronic pain (Jhaveri et al., 2007; Hu et al., 2008).
The inflammatory process can dramatically reduce the level
of endocannabinoids, while its inhibition may contribute to
increased analgesic action. Although widely used in the treatment
of pain, NSAIDs do not always provide adequate relief and have
the risk for serious complications, including death by internal
hemorrhaging (5–10% of chronic NSAIDs therapy) and severe
kidney damage (Rahme and Bernatsky, 2010; Altman, 2011).
However, it should be noted that some of the NSAIDs have the
ability to inhibit FAAH (Fowler et al., 1999; Seidel et al., 2003;
Guindon et al., 2006). Therefore, interaction of NSAIDs with ECS
may be a novel approach for the treatment of chronic pain.
TWO TARGETS: IMPROVEMENT OR
DETERIORATION?
The aging population in developing countries, the lack of
satisfactory therapies, and worldwide increase of chronic pain
are burdens that require the development of new treatments for
pain. A leading approach in the treatment of chronic pain is using
single-target drugs, which are not always effective and can be
associated with many side effects from chronic dosing. Multi-
functional drugs may be advantageous for poorly controlled
chronic pain and may improve safety and efficacy properties
with fewer side effects compared to single-target molecules
(Csermely et al., 2005; Stahl, 2009). Dual-acting compounds also
have much more potential than single-target and highly specific
agents due to better safety profiles and are less likely to exhibit
pharmacokinetic and pharmacological interactions (compared to
combined therapy with two single-target drugs). With respect to
pain relief, there are some reports about multi-target therapeutics
that will be discussed here, including piperazinyl carbamates
that simultaneously interact with FAAH and TRPV1 or FAAH
and COX inhibitors. We will determine the status of in vivo
preclinical drug research and consider whether multi-target
drugs are the current trend in search for better pain therapy
(summarized information on the dual-acting compounds can be
found in the Table 1).
Acting on FAAH and TRPV1
Endogenous levels of AEA can activate but not desensitize
TRPV1 in non-pathological conditions, leading to stimulation
of pain pathways. Elevation of endocannabinoid tone by FAAH
inhibitors may lead to further activation of this channel,
implying that the development of combined FAAH/TRPV1
blockers may have essential therapeutic applications in directing
AEA’s action toward the analgesic CB1/2 pathway. Lack of
efficacy of FAAH inhibitors in patients (as described above)
may be associated with activation of the alternative AEA
biotransformation pathways after completely blocking the FAAH
enzyme and the ability of AEA to induce pro-nociceptive
TABLE 1 | Dual-acting compounds: summary of in vivo studies.
Compound Molecular targets Observed in vivo effect References
AA-5-HT FAAH (inhibition)
TRPV1 (antagonism)
Anti-oedemigen and anti-hyperalgesic in the carrageenan-induced pain;
analgesic in formalin-induced pain; anti-nociceptive in the CCI model; analgesic
in the SNI model
Maione et al., 2007; De Novellis et al.,
2008, 2011; Costa et al., 2010;
Malek et al., 2016
OMDM-198 FAAH (inhibition)
TRPV1 (antagonism)
Anti-nociceptive in the formalin-induced pain; anti-oedemigen in the
carrageenan-induced pain; anti-nociceptive in the MIA model of pain
Maione et al., 2013; Malek et al.,
2015a
Ibuprofen COX-2 (inhibition)
FAAH (inhibition)
Anti-allodynic and anti-hyperalgetic in the PNL model Guindon and Beaulieu, 2006
ARN2508 COX-2 (inhibition)
FAAH (inhibition)
Anti-inflammatory in the model of intestinal inflammation Sasso et al., 2015
CCI, chronic constriction injury; MIA, sodium iodoacetate; PNL, partial sciatic nerve ligation; SNI, spared nerve injury.
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signaling through TRPV1 receptors (Maione et al., 2006; Piscitelli
and Di Marzo, 2012; Starowicz et al., 2013). The most promising
aforementioned agent is the endogenous lipid signaling molecule
N-arachidonoyl-5-hydroxytryptamine (AA-5-HT), which was
originally described as an FAAH inhibitor and called an “unique
dual FAAH/TRPV1 blocker” about a decade later (Maione
et al., 2007). In the context of its inhibitory activity, similar
to other FAAH blockers, AA-5-HT elevates AEA levels in the
CNS and on the periphery (Capasso et al., 2005; Maione et al.,
2007). Moreover, AA-5-HT is able to antagonize human and rat
recombinant TRPV1 receptors with an affinity slightly stronger
than capsaicin, though, it is not clear whether AA-5-HT is
a competitive or non-competitive antagonist (Maione et al.,
2007). AA-5-HT appears to be less effective at TRPV1 blockade
when the pH of the cellular environment is reduced, meaning
that it may be less effective under inflammatory conditions,
although this hypothesis has not been tested in vivo yet (Fowler
et al., 2003; Paylor et al., 2006). Nevertheless, studies involving
a variety of animal models have been conducted to better
understand the mechanism of action of AA-5-HT. A significant
contribution was completed by Maione and colleagues, who
indicated the significant analgesic impact exerted by the
compound in acute and chronic painmodels in rodents following
systemic administration (Maione et al., 2007). A subsequent
study showed that intra-PAG AA-5-HT also causes analgesia
and that the effect is mimicked by co-injection of URB597
and the selective TRPV1 antagonist iodoresiniferatoxin (I-
RTX). Furthermore, antagonizing the CB1 and TRPV1 receptors
abolished AA-5-HT-exerted analgesia, suggesting that these co-
localized receptors are AA-5-HT molecular targets in the PAG
and cortex. Moreover, single AA-5-HT dosages exhibited anti-
allodynic actions more effectively than URB597 or I-RTX (De
Novellis et al., 2008, 2011). In the same series of experiments,
de Novellis et al. determined the role of AA-5-HT in cognitive
and emotional functions (i.e., decision making, goal-directed
behavior and workingmemory) in neuropathic pain. The authors
reported that AA-5-HT is able to restore the balance between
excitatory and inhibitory responses in prefrontal cortex neurons,
highlighting the potential of dual-acting drugs for mitigating the
central sequelae associated with neuropathic pain (De Novellis
et al., 2011). AA-5-HT was also proven to dose-dependently
relieve pain in a model of acute inflammation in mice after
systemic administration (Costa et al., 2010). Its anti-nociceptive
action was associated with an increase in AEA levels in both
inflamed paws and spinal cord, though CB1 and TRPV1 receptors
were differentially involved; TRPV1 was responsible for the
anti-inflammatory properties of AA-5-HT, while both CB1 and
TRPV1 receptors mediated its anti-hyperalgesic activity (Costa
et al., 2010). Our most recent research indicates that CB2
receptors are also involved in the anti-nociceptive actions of
AA-5-HT, after intrathecal administration (Malek et al., 2016).
Despite the fact that AA-5-HT was proven to be active it is
unstable due to effective hydrolysis, therefore efforts to synthesize
AA-5-HT analogs with improved modes of action have been
undertaken (Ortar et al., 2007). The chemical synthesis led
to discovery of piperazinyl carbamates and ureas that are
characterized by higher stability than AA-5-HT, nevertheless
none of them have shown higher efficacy than AA-5-HT
(Ortar et al., 2007, 2013; Morera et al., 2009). Of the many
synthesized compounds, OMDM-198 is best described and tested
in vivo for its anti-nociceptive and analgesic properties. OMDM-
198 exhibits anti-nociceptive, anti-hyperalgesic and anti-edemic
actions in acute and inflammatory pain. It inhibits the second
phase of formalin-induced nociceptive behavior in rodents
and blocks carrageenan-induced thermal hyperalgesia and paw
edema in mice (Maione et al., 2013). The anti-hyperalgesic
effects of OMDM-198 were also evaluated in an animal model
of osteoarthritic pain. It was shown that the effect of OMDM-
198 depends on CB1 receptor activation and TRPV1 receptor
blockade (Malek et al., 2015a). Moreover, OMDM-198 required
lower doses to achieve a comparable analgesic effect than the
two single-target compounds used in the study: URB597 and
SB-366,791 (TRPV1 antagonist; Malek et al., 2015a). These data
suggest that the use of dual-acting compounds may be beneficial
in a matter of side effects characteristic for TRPV1 antagonists
(hyperthermia) and FAAH inhibitors (lack of efficacy in clinics),
because of significant decrease of the working doses. It was shown
that hyperthermia was not observed in animals upon AA-5-
HT treatment (Maione et al., 2007; Costa et al., 2010; Malek
et al., 2016). The same observations were made for OMDM-198
(unpublished data). The field of FAAH/TRPV1 blockers is still
developing. A recently synthesized series of arylboronic acids
characterized by high efficacy on FAAH and TRPV1 have been
reported, though these hybrid compounds have not yet been
evaluated in animal studies for pain (Morera et al., 2016).
Acting on FAAH and COXs
Interactions between COX and FAAH enzymes that control
endogenous lipid (including endocannabinoids) levels were
reported (Guindon and Beaulieu, 2006; Jhaveri et al., 2008).
AEA metabolism is of special interest because blocking FAAH
enzyme activates AEA biotransformation by COX-2 pathway,
leading to decreases in endocannabinoid tone. This may be
another mechanism responsible for lack of analgesic action from
selective FAAH inhibitors (Starowicz et al., 2013; Starowicz
and Di Marzo, 2013). Indeed, co-administration of diclofenac
(NSAID) and URB597 showed synergic analgesic effects in
abdominal pain dependent on both CB1 activation and blocking
prostaglandin production (Naidu et al., 2010). Another study
demonstrated an additive anti-nociceptive activity of PF-3845
and diclofenac in the animal models of inflammatory and
neuropathic pain (Grim et al., 2014). Moreover, ketorolac
(NSAID) was shown to have an additive anti-nociceptive
effect with WIN-55,212-2 (non-selective cannabinoid agonist;
Ulugöl et al., 2006). In these studies, AEA levels were shown
to be elevated with simultaneous inhibition of PG synthesis.
Studies have shown that common NSAIDs (ibuprofen and
flurbiprofen) act also as FAAH inhibitors (Fowler et al., 1999;
Seidel et al., 2003; Guindon et al., 2006). The synergistic
effect of ibuprofen and AEA was proven in experimental
models for acute and neuropathic pain (Guindon and Beaulieu,
2006). Those data demonstrate the rationale underlying design
of novel compounds that can interact with both COXs and
FAAH enzymes. Indeed, numerous novel compounds with
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promising analgesic characteristics were developed recently,
i.e., ARN2508, which was tested and effective in suppressing
intestinal inflammation (Sasso et al., 2015). It also causes no
gastric damage, which is often a case of chronic NSAID treatment
and the protective effect was dependent on FAAH inhibition.
This suggests that COX/FAAH inhibitors shouldn’t exhibit
NSAIDs side effects present during chronic treatment, although
clinical studies would be needed to verify this hypothesis. A panel
of novel ARN2508 derivatives was synthesized, of which (S)-
(+)-ARN2508 demonstrated increased OEA plasma levels and
decreased PGI and TXA levels after intravenous administration
(Migliore et al., 2016). The in vivo results suggest that this
compound may be useful for FAAH-COX related pathologies,
such as pain.
SUMMARY
In this review, we have described the complex network between
TRPV1 and CB1/2 receptors and FAAH and COX-2 enzymes,
which are all involved in anti-nociceptive action of AEA. It
seems that the “single-target” approach is not as effective for
the AEA elevation as this has been characterized by redundancy
of metabolic pathways (by i.e., FAAH, COX). Inhibition of one
enzyme can activate others, leading to absence of anticipated
analgesic effects. The paradigm shift from selective drugs to
multi-target compounds has led to promising results in the
treatment of pain, which has been summarized herein. This
approach may be beneficial for the treatment of pain, which
poses a difficult challenge due to the heterogeneity of its origin.
Compounds, acting on more than one molecular target may have
higher efficacies and better safety profiles than currently used
drugs (and preclinically studied compounds) that act on a single
biological target (Fowler et al., 2009; Boran and Iyengar, 2010).
Acting on more than one target brings a question of selectivity
of dual-acting compounds, which is of concern during the design
phase (Hwang et al., 2013; Aiello et al., 2016). Moreover, as these
molecules are designed to be used for chronic pain treatment
it is crucial to investigate their ability to develop tolerance and
(possibly) dependence, as this was not investigated yet. For
the reviewed compounds no side effects were reported in the
preclinical models of chronic pain, probably due to low doses
necessary to obtain satisfactory pharmacological effect (analgesic,
anti-nociceptive or anti-allodynic). Nevertheless, disadvantages
of the use of multitarget therapy cannot be omitted and its
limitation need to be considered and studied, especially when
safety and efficacy in clinical trials is a major concern (Brodie
et al., 2015).
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